IPP Bureau
Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility
By IPP Bureau - March 09, 2024
The inspection was concluded with few procedural observations
USFDA conducts inspection at Alembic Pharmaceuticals' Panelav oncology formulation facility
By IPP Bureau - March 09, 2024
The company will provide comprehensive response to USFDA for the observations
Remedium Lifecare to acquire manufacturing facility in Hyderabad
By IPP Bureau - March 08, 2024
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
India approves Rs. 10,300 crore for AI Mission
By IPP Bureau - March 08, 2024
The investment will catalyse various components of the IndiaAI Mission
Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
By IPP Bureau - March 07, 2024
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
By IPP Bureau - March 07, 2024
The validations confirm the completion of the applications and commence the scientific review process
Sakar's oncology unit receives EU GMP approval
By IPP Bureau - March 07, 2024
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme
By IPP Bureau - March 07, 2024
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA
By IPP Bureau - March 07, 2024
ANVISA issues CGMP to Concord Biotech’s Unit I
Nectar Lifesciences’ suo moto clarification on a news item
By IPP Bureau - March 07, 2024
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer
By IPP Bureau - March 07, 2024
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Dr. Lal PathLabs CEO Bharath Uppilliappan steps down
By IPP Bureau - March 07, 2024
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Amita Sharma redesignated As COO- API at Morepen Lab
By IPP Bureau - March 07, 2024
Sharma joined the Morepen Lab in 2004
Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility
By IPP Bureau - March 07, 2024
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Strides receives USFDA approval for Gabapentin Tablets
By IPP Bureau - March 06, 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
